AGER and early-onset autosomal dominant Alzheimer disease: TTP488 (Azeliragon; Figure 1), an orally bioavailable small-molecule RAGE inhibitor that binds directly to RAGE and blocks its interaction with all ligands, has been thoroughly investigated in human clinical trials and demonstrated excellent safety in patients with Alzheimer’s disease [34,35].